Anavex Life Sciences said its experimental Alzheimer's treatment met the goals of a midstage study, leading AVXL stock to rocket early Friday.
Yahoo Finance Live’s Brad Smith discusses how markets opened on Friday.
ZIM (ZIM) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
With shares of Axsome Therapeutics (NASDAQ: AXSM) skyrocketing 87% so far this year, the biotech's shareholders are doubtlessly pleased. Thanks to a pair of newly approved products, growth is finally on the way -- with revenue set to go from practically $0 to more than $100 million in the course of a year.
And if you’re behind? It’s OK boomer. There’s still some time to catch up.
In this article we are going to estimate the intrinsic value of Altria Group, Inc. ( NYSE:MO ) by projecting its future...
Trading was halted for AMC after the stock saw heavy volume on Thursday afternoon.
Biotech company Veru (NASDAQ: VERU) aims to make products to treat cancer and infectious diseases. Instead, it has been the company's potential COVID treatment that has been getting investors excited. With the stock recently crashing and now at its lowest levels since March, is now the time to buy shares of Veru?
Telecom giant AT&T (NYSE: T) has been dead money for years. Its share price is down 25% over the past decade. But AT&T's recent success in getting out of the entertainment business and growing its wireless business could change the stock's trajectory.
In this article, we talk about 10 long-term stock picks in billionaire Ray Dalio’s portfolio. If you want to see more stocks in this selection, check out Billionaire Ray Dalio’s 5 Long-Term Stock Picks. Raymond Thomas Dalio is an American billionaire investor and hedge fund manager, who has served as co-chief investment officer of Bridgewater […]
Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner are part of the Zacks Screen of the Week article.
Units of Knot Offshore Partners (NYSE: KNOP) had sunk by more than 18% by 10:30 a.m. ET on Wednesday. Weighing on the master limited partnership (MLP) was an oversupply of shuttle tankers in the North Sea. Knot Offshore Partners issued its third-quarter report, and CEO Gary Chapman said in the accompanying release that its financial results, liquidity, and distributable cash flow "reflect our heavy scheduled drydocking program."
Weaker demand for lumber has weighed on prices, making it one of the biggest commodity price decliners this year. The outlook isn’t good, either.
Yahoo Finance Live examines the state of the mortgage rate landscape as home prices continue to fall.
MarketWatch Picks has highlighted these products and services because we think readers will find them useful; the MarketWatch News staff is not involved in creating this content. “You will want to consider your health, income, expenses, inflation, and other financial goals, as well as whether you have sufficient assets and are confident in your understanding of what retirement entails.”
The Labor Department monthly jobs report for November at 8:30 a.m. ET on Friday. Here are the highlights, compared to Wall Street estimates.
Wedbush on Friday launched coverage of Green Thumb Industries Inc. , Cresco Labs Inc. , Curaleaf Holdings Inc. and Trulieve Cannabis Corp. with outperform ratings. Analyst Gerald Pascarelli said of the four cannabis companies Green Thumb Industries ranks as Wedbush's top pick. "We believe that brighter days lie ahead for the U.S. cannabis industry and that incremental revenues from new states slated to come online for adult use sales, coupled with a normalization in trend in legacy markets, as w
No one can say whether that will happen next year, but even if it doesn't, there are plenty of companies that can deliver excellent returns despite heightened market volatility and a struggling economy. Let's consider two examples: Eli Lilly (NYSE: LLY) and Visa (NYSE: V). Pharma giant Eli Lilly has been flying high all year despite its financial results not being particularly impressive.
Highlights HF Sinclair, DCP Midstream, Arista Networks, Fortinet, Texas Pacific Land are part of the Zacks top Analyst blog.